ABOUT

Merial vaccines for quality and safety you can rely on.

At Merial, we are proud to offer the quality vaccines that support both your practice and your patients’ good health, including:

IMRAB®, the world’s leading rabies vaccine

PUREVAX® state-of-the-art family of vaccines for cats and kittens

RECOMBITEK® family of vaccines for puppies and dogs

IMRAB, a leader in rabies vaccine.1

IMRAB offers many unique advantages to veterinarians — and the animals in their care:

  • IMRAB 3 is indicated for use in six species (dogs, cats, ferrets, horses, cattle, and sheep), so clinics only need to stock a single rabies vaccine.
    • Three-year duration of immunity in dogs, cats, and sheep2
    • One-year duration of immunity in horses, ferrets, and cattle2
  • IMRAB also is available in the following forms:
    • IMRAB 3 TF (thimerosal-free formulation) provides three years of rabies protection for dogs and cats and one year for ferrets3
    • IMRAB 1 — provides one year of protection for dogs and cats4
    • IMRAB 1 TF (thimerosal-free) provides one year of rabies protection for dogs and cats5
  • IMRAB has been widely used for more than 30 years — with millions of animals protected against rabies.1
    • Highly purified, inactivated virus used in vaccine production.
    • Smooth, easy subcutaneous or intramuscular injection (subcutaneous only for ferrets).2,3
    • IMRAB is a direct descendant of the world’s very first rabies vaccines from Institute Pasteur-Mérieux.

You know the dangers of rabies. Protect pets and people from this deadly zoonotic disease with IMRAB, the world’s leading rabies vaccine.

Back to top

PUREVAX, for the protection of felines.

PUREVAX, the industry-leading line of nonadjuvanted feline vaccines that helps protect cats against a number of diseases, including rabies, feline leukemia virus (FeLV), panleukopenia, and pathogens that commonly cause respiratory disease in cats. The family of PUREVAX vaccines induces immunity without any adjuvants that can present potential risks to cats.

  • PUREVAX Recombinant FeLV — canarypox-vectored recombinant vaccine is recommended for the vaccination of healthy cats 8 weeks of age and older for prevention of disease due to feline leukemia virus.6
  • PUREVAX Feline Rabies (rRabies) 1-year Rabies — canarypox-vectored recombinant, 1-year duration of immunity, is recommended for the vaccination of healthy cats 8 weeks of age or older for prevention of disease due to rabies virus.7
  • PUREVAX Feline Rabies (rRabies) 3-year Rabies — canarypox-vectored recombinant, 3-year duration of immunity, is recommended for the vaccination of healthy cats 12 weeks of age or older for prevention of disease due to rabies virus.8
  • PUREVAX FELINE RESPIRATORY 2 Feline Rhinotracheitis-Calici Vaccine Modified Live Virus is recommended for the vaccination of healthy cats 6 weeks of age and older for prevention of disease due to feline rhinotracheitis and calici viruses.9
  • PUREVAX FELINE RESPIRATORY 3 Feline Rhinotracheitis-Calici-Chlamydia psittaci Vaccine Modified Live Virus and Chlamydia is recommended for the vaccination of healthy cats 6 weeks of age and older for prevention of disease due to feline rhinotracheitis, calicivirus, and as an aid in the reduction of disease due to Chlamydia psittaci.10
  • PUREVAX FELINE 3 Feline Rhinotracheitis-Calici-Panleukopenia Vaccine Modified Live Virus is recommended for the vaccination of healthy cats for prevention of disease due to feline rhinotracheitis, calici, and panleukopenia viruses.11
  • PUREVAX FELINE 3 + RABIES Feline Rhinotracheitis-Calici- Panleukopenia-Rabies Vaccine Modified Live Virus, Canarypox Vector is recommended for the vaccination of healthy cats 8 weeks of age or older for prevention of disease due to feline rhinotracheitis, calici, panleukopenia, and rabies viruses.12
  • PUREVAX FELINE 4 Feline Rhinotracheitis-Calici-Panleukopenia- Chlamydia psittaci Vaccine is recommended for the vaccination of healthy cats 6 weeks of age and older for prevention of disease due to feline rhinotracheitis, calici, and panleukopenia viruses and as an aid in the reduction of disease due to Chlamydia psittaci.13
  • PUREVAX FELINE 4 + RABIES Feline Rhinotracheitis-Calici-Panleukopenia- Chlamydia psittaci-Rabies Vaccine Modified Live Virus and Chlamydia, Canarypox Vector is recommended for the vaccination of healthy cats 8 weeks of age and older for prevention of disease due to feline rhinotracheitis, calici, panleukopenia, and rabies viruses and as an aid in the reduction of disease due to Chlamydia psittaci.14
Back to top
Vaccines Desiccants Diluent
PUREVAX®
Recombinant FeLV

25 x 1 dose/1mL dose
Feline Leukemia —
canarypox-vectored
recombinant
Sterile
Water
PUREVAX Feline Rabies
(rRabies)1-year

25 x 1 dose/1mL dose
Rabies — canarypox-vectored
recombinant, 1-year duration
of immunity
Sterile
Water
PUREVAX Feline Rabies
(rRabies) 3-year

25 x 1 dose/1mL dose
Rabies — canarypox-vectored
recombinant, 3-year duration
of immunity
Sterile
Water
PUREVAX Feline Respiratory
2 (RC)

25 x 1 dose/1mL dose
Rhinotracheitis — MLV
Calicivirus — MLV
Sterile
Water
PUREVAX Feline Respiratory
3 (RCC)

25 x 1 dose/1mL dose
Rhinotracheitis — MLV
Calicivirus — MLV
Chlamydophila — ML
Sterile
Water
PUREVAX Feline 3 (RCP)
25 x 1 dose/1mL dose
Rhinotracheitis — MLV
Calicivirus — MLV
Panleukopenia — MLV
Sterile
Water
PUREVAX Feline 4 (RCCP)
25 x 1 dose/1mL dose
Rhinotracheitis — MLV
Calicivirus — MLV
Chlamydophila — ML
Panleukopenia — MLV
Sterile
Water
PUREVAX Feline 3/Rabies
(RCP + rRabies)

25 x 1 dose/1mL dose
Rhinotracheitis — MLV
Calicivirus — MLV
Panleukopenia — MLV
Rabies — canarypox-vectored
recombinant, 1-year duration
of immunity
Sterile
Water
PUREVAX Feline 4/Rabies
(RCCP + rRabies)

25 x 1 dose/1mL dose
Rhinotracheitis — MLV
Calicivirus — MLV
Chlamydophila — ML
Panleukopenia — MLV
Rabies — canarypox-vectored
recombinant, 1-year duration
of immunity
Sterile
Water

RECOMBITEK, for the protection of canines.

The RECOMBITEK family of vaccines have been proven safe and effective to protect puppies and dogs from a variety of diseases. For some vaccines, extensive research and the use of advanced science (recombinant technology) may help protect your pet without adjuvants and the potential risks of those adjuvants. Learn more about recombinant vaccines here.

RECOMBITEK Distemper

  • RECOMBITEK C3 (rDAP)
  • RECOMBITEK C4 (rDAPP)
  • RECOMBITEK C4/CV (rDAPPC)
  • RECOMBITEK C6 (rDAPP-LCI)
  • RECOMBITEK C6/CV (rDAPPC-LCI)

RECOMBITEK Lepto

RECOMBITEK Lyme

RECOMBITEK Canine Parvo

RECOMBITEK Canine Corona-MLV

RECOMBITEK Canine Parvo + Corona-MLV

RECOMBITEK Lyme

Targeted protection through recombinant technology.

By using only pure outer surface protein A (OspA), RECOMBITEK Lyme provides efficacy without the potentially harmful flagellan protein.15 Plus, RECOMBITEK Lyme contains no chemical adjuvants, thus eliminating the potential risk typically associated with adjuvants.

  • Recombinant subunit technology uses only a pure non-adjuvanted protein to stimulate immunity
  • In one study, shown to completely block transmission of Lyme disease spirochete16
  • Not a wholeell bacteria
Back to top

RECOMBITEK rDistemper

Recombinant-vectored vaccine for targeted protection.

Through the advanced technology of Type 3 recombinant vaccine manufacturing, RECOMBITEK rDistemper offers safe, proven, efficacious distemper protection for your canine patients17

  • Contains both the HA (hemagglutinin) and F (fusion membrane protein) antigens
  • Used throughout North America and South America, including highly endemic are of Mexico and Brazil
Back to top

RECOMBITEK Lepto

RECOMBITEK Lepto protects against causative agents of canine leptospirosis.18

  • Protects against shedding spirochetes that transmit disease
  • Provided 100% protection against Leptospira grippotyphosa even when vaccinates were commingled with control dogs actively shedding spirochetes
  • Non-adjuvanted
Back to top

RECOMBITEK Canine Parvo

Powerful protection for puppies.

RECOMBITEK Canine Parvo helps close the window of vulnerability to canine parvovirus (CPV), even in puppies born with high levels of maternal antibodies. While declining levels of maternal antibodies may not protect puppies from viral infection, they may interfere with the effectiveness of a vaccine. RECOMBITEK Canine Parvo breaks through maternal antibodies to provide safe, proven, powerful protection.

  • Proven protection against CPV by 12 weeks of age19
  • High-titer, low-passage profile helps break through maternal antibodies
  • Protects against CPV2a and CPV2b
  • Non-immunosuppressive with no reversion to virulence
  • Millions of doses sold throughout North America and South America1
Back to top

RECOMBITEK Corona MLV

The only modified-live corona vaccine available

RECOMBITEK Corona MLV is the only modified-live, canine-origin coronavirus available today, providing early rapid protection against canine coronavirus (CCV).

  • Prevents intestinal damage20
  • Prevents shedding of virulent virus20
  • No virus isolated in over 90% of small intestine samples20
  • Rapid, early protection against clinical signs of CCV20
  • Proven protection in the face of maternal antibodies
Back to top

RECOMBITEK Canine Parvo + Corona-MLV

RECOMBITEK Canine Parvo + Corona-MLV combines the benefits of RECOMBITEK Canine Parvo and RECOMBITEK Canine Corona-MLV in one vaccine.

Back to top
Vaccines Desiccants Diluent
RECOMBITEK® C3
(rDAP)

25 x 1 dose/1mL dose
Distemper — canarypox-vectored
recombinant
Adenovirus — MLV, type 2
Parvovirus — MLV, low-passage,
high-titer
Sterile Water
RECOMBITEK C4
(rDAPP)

25 x 1 dose/1mL dose
Distemper — canarypox-vectored
recombinant
Adenovirus — MLV, type 2
Parainfluenza — MLV
Parvovirus — MLV, low-passage,
high-titer
Sterile Water
RECOMBITEK C4/CV
(rDAPPC)

25 x 1 dose/1mL dose
Distemper — canarypox-vectored
recombinant
Adenovirus — MLV, type 2
Parainfluenza — MLV
Parvovirus — MLV, low-passage,
high-titer
Coronavirus — MLV
Sterile Water
RECOMBITEK C6
(rDAPP-LCI)

25 x 1 dose/1mL dose
Distemper — canarypox-vectored
recombinant
Adenovirus — MLV, type 2
Parainfluenza — MLV
Parvovirus — MLV, low-passage,
high-titer
Leptospira — killed,
L. canicola and
L. icterohaemorrhagiae
RECOMBITEK C6/CV
(rDAPPC-LCI)

25 x 1 dose/1mL dose
Distemper — canarypox-vectored
recombinant
Adenovirus — MLV, type 2
Parainfluenza — MLV
Parvovirus — MLV, low-passage,
high-titer
Coronavirus — MLV
Leptospira — killed,
L. canicola and
L. icterohaemorrhagiae
RECOMBITEK 4 Lepto
(LCGIP)

50 x 1 dose/1mL dose
None Leptospira — killed,
L. canicola, L. grippotyphosa,
L. icterohaemorrhagiae and
L. pomona
RECOMBITEK Lyme
(rLyme)

50 x 1 dose/1mL dose
20 x 1 dose/1mL dose
None Lyme — recombinant,
OspA from Borrelia
burgdorferi spirochete
RECOMBITEK Canine
Parvo (CPV)

50 x 1 dose/1mL dose
None Parvovirus — MLV,
low-passage, high-titer
RECOMBITEK Canine
Corona-MLV (CCV)

25 x 1 dose/1mL dose
Coronavirus — MLV Sterile Water
RECOMBITEK Canine
Parvo + Corona-MLV

(CPV + CCV)
25 x 1 dose/1mL dose
Coronavirus — MLV Parvovirus — MLV,
low-passage, high-titer

What is recombinant technology?21,22

Traditionally, vaccines are made by killing or attenuating the disease-causing pathogen and injecting it into the patient to trigger the patient's immune system to produce antibodies or activated T-cells for protection against the disease. Then, if the patient comes in natural contact with the disease-causing virus or bacteria, the body's immune system is already primed to recognize the specific organism invader and armed to fight it off.

Recombinant vaccine, such as Recombitek Distemper, consists of a carrier or vector that carries a small portion of the genetic material of the disease-causing virus. When introduced (and expressed) in the patient’s body, recombinant vaccines can trigger robust protective immunity targeting the pathogenic organism. Because only genetic fragments, and not the complete pathogenic organism, are incorporated into the vector, it is not possible for the recombinant vaccine to produce active disease in the vaccinated animal.

Back to top

REFERENCES: 1. Data on file at Merial. 2. IMRAB 3 Product Label. 3. IMRAB 3 TF Product Label. 4. IMRAB 1 Product Label. 5. IMRAB 1 TF Product Label. 6. PUREVAX FeLV Product Label. 7. PUREVAX Feline 1-year Rabies Product Label. 8. PUREVAX Feline 3-year Rabies Product Label. 9. PUREVAX Feline Respiratory 2 Product Label. 10. PUREVAX Feline Respiratory 3 Product Label . 11. PUREVAX Feline 3 Product Label. 12. PUREVAX Feline 3 Rabies Product Label. 13. PUREVAX Feline 4 Product Label. 14. PUREVAX Feline 4 Rabies Product Label. 15. Wormser GP. Clin Infect Dis. 1995;21:1267-1274. 16. Conlon JAR, et al. Vet Ther. 2000;1:96-107. 17. Pardo MC, Tanner P, Bauman J, et al. Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus. J Comp Path. 2007;137:S72-S75. 18. RECOMBITEK 4 Lepto Product Label. 19. RECOMBITEK Canine Parvo Product Label. 20. Pardo MC, Mackowiak M. Efficacy of a new canine-origin, modified-live virus vaccine against canine coronavirus. Canine Practice. 1999;24:6-8. 21. National Institute of Allergy and Infectious Diseases. Types of vaccines. http://www.niaid.nih.gov/topics/ vaccines/understanding/pages/typesvaccines.aspx. Accessed March 29, 2015. 22. Taylor J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995;13(6):539-549.